Skip to main content

Chicago's Sparx Therapeutics to Build Biologics Manufacturing Facility in China

Sparx Therapeutics, a Chicago antibody drug conjugate (ADC) company, will build a 1.2 million square-foot manufacturing facility in Yangzhou , which is west of Shanghai . Sparx uses AI to drive its proprietary target mining platform, identifying cellular targets that offer optimal and synergistic biological activity. The targets are refined by the company's multi-component Sailing™ antibody optimization system and four cutting-edge ADC technologies to improve the success rate. Dr. Gui-Dong Zhu, the CEO of Sparx, has signed a 20-year lease agreement for the facility with Yangzhou Economic Zone. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.